Black, Elderly Patients Less Likely to Receive Treatment for Lung Cancer
About a fifth of patients with lung cancer in the United States receive no treatment at all, while approximately 6 in 10 receive the minimal treatments recommended by the National Comprehensive Cancer Network.
MD Anderson Partners with Takeda to Develop CAR Natural Killer-Cell Therapy
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited have entered an exclusive license agreement and research agreement to develop and market chimeric antigen receptor-directed natural killer-cell therapies.
Cancer Center Aims to Evaluate Proton Therapy in NSCLC
Proton therapy’s direct and precise application of radiation for mid-stage lung cancer is being investigated in an ongoing phase III trial at the University of Cincinnati.
UK Researchers Develop Blood Test for Breast Cancer Diagnosis
A blood test which may detect the traces of developing breast cancer through autoantibodies years before clinical signs show themselves is now proposed by researchers in the United Kingdom.
Certain Chemo May Cause Mutations in ALL Recurrence
A new study in the Journal of Clinical Oncology finds that a subset of pediatric ALL relapses may be triggered by the very chemotherapy which helped patients beat the cancer the first time.
Genomic Testing Costs Not Always Addressed by Oncologists, Survey Says
Conversations about the financial realities of genomic testing are not always taking place, according to a new study by the American Cancer Society.
Lenvatinib, Pembrolizumab Combo Shows Promising Results in Metastatic RCC
Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor.
Expert Discusses Service Focused on Immunotherapy-Related AEs
Massachusetts General Hospital’s Severe Immunotherapy Complications Service focuses on the increasing number of “rare” cases of immunotherapy-related adverse events.
Investigational Drug Shows Promise in Diffuse Large B-Cell Lymphoma
A new investigational drug called ADCT-402 that combines a cell-killing compound with a monoclonal antibody shows early promise for patients with diffuse large B-cell lymphoma.
Ultrasound Plus Machine Learning Identifies Thyroid Cancer
Machine learning of ultrasound scans could provide a preliminary method of screening for thyroid cancer.
Yogurt, Fiber Consumption May Be Associated With Decreased Risk for Lung Cancer
The probiotics and prebiotics of yogurt and fiber consumption is associated with decreased risk of lung cancer.
Early Chemo Does Not Improve Survival in Endometrial Cancer
Endometrial cancer survival correlates with total number of chemotherapy cycles – but not whether they are started earlier than radiation, according to the results of a new study.
MRTX849 Shows Clinical Activity in KRAS G12C-Mutant Cancers
A compound called MRTX849 is showing signs of being the first effective inhibitor of the KRAS G12C-mutant subtype of non-small cell lung and colorectal cancers.
RNA Sequencing Shows Epigenetics Behind Pediatric Cancer
Using RNA sequencing for individual pediatric cancer cases could more effectively target gene expression in tumors.
Danish Team Discovers Possible Cancer Culprit: ‘Protein Scaffolding’ for DNA Repair
Tipifarnib Shows Responses in HRAS-Mutant Head and Neck Cancers
A new inhibitor may help patients with a certain subset of head and neck squamous cell carcinoma.
Smoldering Multiple Myeloma Can Be Slowed by Lenalidomide
Early treatment with lenalidomide can stave off multiple myeloma and provide longer progression-free survival (PFS) than just monitoring alone.
Can Machine Learning Help Anticipate Death from Cancer?
A new machine-learning computer model helped predict which patients of cancer may die soon.
Selumetinib Clinically Improves NF1-Associated Neurofibromas
The MEK inhibitor selumetinib showed clinical responses in the plexiform neurofibromas of adult patients with neurofibromatosis type 1.
Patient-Reported Outcomes Bolster Breast Cancer Treatment
Patients, providers, and healthcare processes benefit from systematically collecting patient-reported outcomes and reviews of their experiences in breast cancer treatment.
Pancreatic and Colorectal Cancer Cases See Sharp Increase
The worldwide incidence, and death toll, of colorectal and pancreatic cancers have sharply increased since 1990, according to the results of a new study.
Blood Test of Circulating Cell-Free DNA Could Flag Most Stubborn B-Cell Lymphoma
The epigenetic signals in circulating cell-free DNA (cfDNA) in patients diagnosed with diffuse large B-cell lymphoma (DLBCL) could predict which cases are the most likely to recur.
Metabolic Imbalance Linked to Immune Checkpoint Blocker Resistance
Conversion of tryptophan to kynurenine was associated with lower survival rates.
Immunotherapy Responses Differ by Sex, Study Says
Immunotherapy responses may not be equal between the sexes.
FDA Approves Test for Late-line HRD+ Ovarian Cancer
The approval comes one day after the FDA approved niraparib for the same subset of ovarian cancer.
Tucatinib Improves PFS, OS in HER2-Positive Metastatic Breast Cancer
Tucatinib showed improvements in survival in patients with HER2-positive breast cancer.
MicroRNA Expression Tied to Triple-Negative Breast Cancer in Latin America
The results of this new study could also further explain the patterns of tumor development among certain ethnicities.
Cancer Atlas Points to Global Burden of Alcohol as Carcinogen
Alcohol has been labeled a carcinogen by a growing number of agencies across the globe, after years of scientific and policy debate. But just how much of the cancer burden is it responsible for?
AI and Radiologists Together: Better Breast Cancer Diagnoses?
Radiologists and data scientists decided to get together to evaluate the effectiveness of artificial intelligence and human observation when it comes to detecting breast cancer in mammograms.
Niraparib for Advanced Ovarian Cancer with HRD+ Status Approved by FDA
Niraparib was approved by the (FDA) for previously treated advanced ovarian, fallopian, or primary peritoneal cancers.
2 Clarke Drive Cranbury, NJ 08512